These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 33038544)

  • 1. Hit-to-lead optimization and discovery of a potent, and orally bioavailable G protein coupled receptor kinase 2 (GRK2) inhibitor.
    Xu G; Gaul MD; Liu Z; DesJarlais RL; Qi J; Wang W; Krosky D; Petrounia I; Milligan CM; Hermans A; Lu HR; Huang DZ; Xu JZ; Spurlino JC
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127602. PubMed ID: 33038544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure.
    Okawa T; Aramaki Y; Yamamoto M; Kobayashi T; Fukumoto S; Toyoda Y; Henta T; Hata A; Ikeda S; Kaneko M; Hoffman ID; Sang BC; Zou H; Kawamoto T
    J Med Chem; 2017 Aug; 60(16):6942-6990. PubMed ID: 28699740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilizing a structure-based docking approach to develop potent G protein-coupled receptor kinase (GRK) 2 and 5 inhibitors.
    Waldschmidt HV; Bouley R; Kirchhoff PD; Lee P; Tesmer JJG; Larsen SD
    Bioorg Med Chem Lett; 2018 May; 28(9):1507-1515. PubMed ID: 29627263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitors: Current Trends and Future Perspectives.
    Guccione M; Ettari R; Taliani S; Da Settimo F; Zappalà M; Grasso S
    J Med Chem; 2016 Oct; 59(20):9277-9294. PubMed ID: 27362616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and efficacy of novel G protein-coupled receptor kinase 2 inhibitors.
    Carotenuto A; Cipolletta E; Gomez-Monterrey I; Sala M; Vernieri E; Limatola A; Bertamino A; Musella S; Sorriento D; Grieco P; Trimarco B; Novellino E; Iaccarino G; Campiglia P
    Eur J Med Chem; 2013 Nov; 69():384-92. PubMed ID: 24077529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.
    Waldschmidt HV; Homan KT; Cato MC; Cruz-Rodríguez O; Cannavo A; Wilson MW; Song J; Cheung JY; Koch WJ; Tesmer JJ; Larsen SD
    J Med Chem; 2017 Apr; 60(7):3052-3069. PubMed ID: 28323425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of inhibitors of the RGS homology domain of GRK2 by docking-based virtual screening.
    Echeverría E; Velez Rueda AJ; Cabrera M; Juritz E; Burghi V; Fabián L; Davio C; Lorenzano Menna P; Fernández NC
    Life Sci; 2019 Dec; 239():116872. PubMed ID: 31525427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac hyporesponsiveness in severe sepsis is associated with nitric oxide-dependent activation of G protein receptor kinase.
    Dal-Secco D; DalBó S; Lautherbach NES; Gava FN; Celes MRN; Benedet PO; Souza AH; Akinaga J; Lima V; Silva KP; Kiguti LRA; Rossi MA; Kettelhut IC; Pupo AS; Cunha FQ; Assreuy J
    Am J Physiol Heart Circ Physiol; 2017 Jul; 313(1):H149-H163. PubMed ID: 28526706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility.
    Thal DM; Homan KT; Chen J; Wu EK; Hinkle PM; Huang ZM; Chuprun JK; Song J; Gao E; Cheung JY; Sklar LA; Koch WJ; Tesmer JJ
    ACS Chem Biol; 2012 Nov; 7(11):1830-9. PubMed ID: 22882301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction.
    Schumacher SM; Gao E; Zhu W; Chen X; Chuprun JK; Feldman AM; Tesmer JJ; Koch WJ
    Sci Transl Med; 2015 Mar; 7(277):277ra31. PubMed ID: 25739765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GRK2 inhibition in heart failure: something old, something new.
    Lymperopoulos A; Rengo G; Koch WJ
    Curr Pharm Des; 2012; 18(2):186-91. PubMed ID: 22229578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The N-termini of GRK2 and GRK3 simulate the stimulating effects of RKIP on β-adrenoceptors.
    Maimari T; Krasel C; Bünemann M; Lorenz K
    Biochem Biophys Res Commun; 2019 Dec; 520(2):327-332. PubMed ID: 31604529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational study of paroxetine-like inhibitors reveals new molecular insight to inhibit GRK2 with selectivity over ROCK1.
    Keretsu S; Bhujbal SP; Joo Cho S
    Sci Rep; 2019 Sep; 9(1):13053. PubMed ID: 31506468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia.
    Ciccarelli M; Chuprun JK; Rengo G; Gao E; Wei Z; Peroutka RJ; Gold JI; Gumpert A; Chen M; Otis NJ; Dorn GW; Trimarco B; Iaccarino G; Koch WJ
    Circulation; 2011 May; 123(18):1953-62. PubMed ID: 21518983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of cellular oxidative stress and apoptosis by G protein-coupled receptor kinase-2; The role of NADPH oxidase 4.
    Theccanat T; Philip JL; Razzaque AM; Ludmer N; Li J; Xu X; Akhter SA
    Cell Signal; 2016 Mar; 28(3):190-203. PubMed ID: 26631573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prodeath signaling of G protein-coupled receptor kinase 2 in cardiac myocytes after ischemic stress occurs via extracellular signal-regulated kinase-dependent heat shock protein 90-mediated mitochondrial targeting.
    Chen M; Sato PY; Chuprun JK; Peroutka RJ; Otis NJ; Ibetti J; Pan S; Sheu SS; Gao E; Koch WJ
    Circ Res; 2013 Apr; 112(8):1121-34. PubMed ID: 23467820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G protein-coupled receptor kinase 2 contributes to impaired fatty acid metabolism in the failing heart.
    Pfleger J; Gross P; Johnson J; Carter RL; Gao E; Tilley DG; Houser SR; Koch WJ
    J Mol Cell Cardiol; 2018 Oct; 123():108-117. PubMed ID: 30171848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GRK2 as a therapeutic target for heart failure.
    Cannavo A; Komici K; Bencivenga L; D'amico ML; Gambino G; Liccardo D; Ferrara N; Rengo G
    Expert Opin Ther Targets; 2018 Jan; 22(1):75-83. PubMed ID: 29166798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors.
    Cho SY; Lee BH; Jung H; Yun CS; Ha JD; Kim HR; Chae CH; Lee JH; Seo HW; Oh KS
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6711-6. PubMed ID: 24210504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of G-protein-coupled receptor kinase 2 (GRK2) triggers the growth-promoting mitogen-activated protein kinase (MAPK) pathway.
    Fu X; Koller S; Abd Alla J; Quitterer U
    J Biol Chem; 2013 Mar; 288(11):7738-7755. PubMed ID: 23362259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.